Protocol approach: frozen shoulder (adhesive capsulitis) Goal: Reduce capsular fibrosis, restore range of motion, manage pain Peptide approach: BPC-157: 300 to 500 mcg daily for anti-inflammatory and tissue healing properties TB-500: 500 to 750 mcg twice weekly for systemic anti-inflammatory and tissue remodeling Note on relaxin-2: While the most specifically targeted peptide for this condition, it remains largely in the research phase and is not widely available through standard channels Duration: Twelve to sixteen weeks (frozen shoulder has a prolonged natural course) Critical addition: Aggressive physical therapy within pain tolerance
Research-Use Labelling and Canadian Compliance Requirements Canadian regulatory framing for injectable peptides has tightened throughout 2025 and 2026, and BPC-157 in particular has been named in multiple Health Canada advisories
siRNA knockdown Mission esiRNAs targeting human TMEM33 (EHU035611), EGFP (EHUEGFP), murine Tmem33 (Emu078331), murine Fads2 (EMU027741), murine Scd1 (EMU023031) and murine Hsd17b12 (EMU064031) were purchased from Sigma
These compounds work by blocking damaging pathways, clearing senescent cells, and activating RXFP1 receptors to limit scarring
These agents can lead to the development of arrhythmias, with AF being the most common manifestation
